Advertisement
Table 1 Baseline characteristics of groups 1 & 2; risk factors, tumor characteristics, and treatment
| Characteristic | Group 1 | Group 2 |
|---|---|---|
| n = 101 | n = 22 | |
| Age at diagnosis, | ||
| (years); ±SD | 36.9 ± 5.2 | 53.1 ± 4.8 |
| Familial cancer | ||
| n (%) | 54 (53%) | 0 |
| BMI, | ||
| mean; ±SD | 27.7 ± 5.3 | 27.1 ± 4.2 |
| Age at menarche | ||
| mean ± SD | 12.3 ± 1.4 | 12.7 ± 1.3 |
| Parity | ||
| mean ± SD | 2.4 ± 1.6 | 3.6 ± 2.1 |
| Nuliparous; n (%) | 18 (18%) | 1 (5%) |
| Age at first pregnancy | ||
| mean ± SD | 21 ± 5.4 | 23 ± 5.6 |
| Breastfeeding; n (%) | 48/76 (63%) | 11/20 (55%) |
| Contraceptive use; n (%) | 38/97 (39%) | 8/20 (40%) |
| Smoking; n (%) | 17 (17%) | 7 (32%) |
| Histology; n (%) | ||
| Ductal | 80/90 (89%) | 18/22 (82%) |
| Other | 10/90 (11%) | 4/22 (18%) |
| Nuclear Grade; n (%) | ||
| 2 | 31/80 (39%) | 18/21 (86%) |
| 3 | 42/80 (53%) | 2/21 (10%) |
| Stage; n (%) | ||
| 0 | 1/101 (1%) | 1. (0) |
| I–II | 57/101 (56%) | 17/22 (77) |
| III | 39/101 (39%) | 5/22 (23) |
| IV | 4/101 (4%) | 0 (0) |
| T; n (%) | ||
| 0–1 | 29/100 (29%) | 11/22 (50) |
| 2 | 37/100 (37%) | 7/22 (32) |
| 3 | 25/100 (25%) | 3/22 (14) |
| 4 | 9/100 (9%) | 1/22 (4) |
| N; n (%) | ||
| Positive | 59/99 (60%) | 12/22 (55%) |
| IHC; n (%) | ||
| ER (+) | 52/95 (55%) | 22/22 (100%) |
| PR (+) | 47/95 (49%) | 21/22 (95%) |
| HER (+) | 19/93 (20%) | 5/22 (23%) |
| Triple negative | 30/93 (32%) | 0 (0%) |
| Surgery type; n (%) | ||
| Radical mastectomy | 80/99 (81%) | 10/22 (45%) |
| Breast conservative | 18/99 (18%) | 12/22 (55%) |
| Chemotherapy; n (%) | ||
| Neoadjuvant | 28/100 (28%) | 4/22 (18%) |
| Adjuvant | 62/100 (62%) | 15/22 (68%) |
| Anthrac. based | 9/62 (15%) | 7/15 (40%) |
| Anthrac/Taxane. | 45/62 (72%) | 6/15 (47%) |
